Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ACVR1C siRNA
- Development stage
- Preclinical
- Lead developer
- Sanegene Bio
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
SanegeneBio's ACVR1C siRNA is a preclinical RNA interference (RNAi) therapeutic candidate being developed for the treatment of obesity and cardiometabolic diseases. The drug utilizes small interfering RNA (siRNA) to specifically target and silence the expression of the *ACVR1C* gene (Activin A receptor type 1C, also known as ALK7) in the liver. ACVR1C is a type I receptor for the TGF-beta superfamily that has been identified as a potential target for metabolic disorders due to its role in regulating adiposity and insulin sensitivity. By reducing ACVR1C levels, the therapy aims to improve metabolic profiles and facilitate weight loss. The program is currently in the lead identification and preclinical testing phase and is part of SanegeneBio's LEAD (Liver-targeting Efficient delivery of siRNA) platform.
- Other names
- Suzhou Shengyin Biopharmaceutical-ACVR1C-RNAi (siRNA)-Obesity-Cardiometabolic diseases
02
Targets
ACVR1C (Activin A Receptor Type 1C)
Beyond the preview
Go deeper on ACVR1C siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ACVR1C siRNA.